Titan Appoints Federico Seghi Recli to Board of Directors
16 May 2018 - - South San Francisco, California-based proprietary therapeutics developer Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has named Federico Seghi Recli to its board of directors, the company said.
An executive with over 24 years of leadership experience within the pharmaceutical industry, Seghi Recli has served in a number of executive positions with L. Molteni and C. dei F. lli Alitti Società di Esercizio S.p.A., which, in March 2018, acquired European Probuphine intellectual property from Titan and expects to commercialise the product in Europeand other select territories following regulatory approvals.
In his most recent role as chief executive officer, he led Molteni's successful transformation into a specialty pharmaceutical company focused on launching and commercializing innovative pharmaceutical products for the treatment of pain and addiction.
Today, Molteni operates both directly and through its network of specialized partners in more than 30 countries and is a preferred and qualified partner of international organizations and non-governmental organizations.
Seghi Recli's career experience also includes senior roles with Merck S.p.A, including president and CEO from 2002 until 2005.
Titan is developing proprietary therapeutics primarily for the treatment of serious medical disorders.
The company's lead product is Probuphine, a novel and long-acting formulation of buprenorphine that provides continuous blood levels of buprenorphine for six months following a single procedure, employs Titan's proprietary drug delivery system ProNeura, which is capable of delivering sustained, consistent levels of medication for three months or longer.